Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Toronto Stock Exchange  >  ProMIS Neurosciences, Inc.    PMN   CA74346M1095

PROMIS NEUROSCIENCES, INC.

(PMN)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo ProMIS Neurosciences, Inc.
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and AMFIA. It is developing therapies targeting misfolded, neurotoxic forms of Amyloid beta in AD and superoxide dismutase 1 (SOD1) in ALS. The Company focuses to use its platform to discover further targets for precision medicine solutions through identification of target epitopes on other misfolded strains of Amyloid beta. The Company focuses to evaluate targets on misfolded strains of tau, another protein implicated in neurodegenerative diseases, including Alzheimer's. The Company has not generated any product revenues.
Sales per Business
20182019Delta
CAD (in Million)%CAD (in Million)%
Precision Medicine Solutions0.000100%0.001100% +153.05%
Sales per region
20182019Delta
CAD (in Million)%CAD (in Million)%
Canada0.000100%0.001100% +153.05%
Managers
NameAgeSinceTitle
Elliot Goldstein, Dr.682015President, Chief Executive Officer & Director
Eugene Williams592015Executive Chairman
Daniel E. Geffken612017Chief Financial Officer
Neil R. Cashman, Dr.-2015Director & Chief Scientific Officer
James Kupiec, Dr.-2018Chief Medical Officer
Johannes Minho Roth392014Independent Director
William W. Wyman812015Independent Director
Patrick D. Kirwin-2015Independent Director
Richard J. Gregory, Dr.612016Independent Director
Anthony J. Giovinazzo622017Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 280,198,484 247,673,824 88.4% 0 0.0% 88.4%
Shareholders
NameEquities%
Eugene Williams 7,795,483 2.82%
Elliot Goldstein 7,199,566 2.60%
Neil R. Cashman 5,822,311 2.11%
William W. Wyman 3,503,333 1.27%
Patrick D. Kirwin 3,099,750 1.12%
Anthony J. Giovinazzo 1,285,000 0.46%
Johanne Kaplan 289,017 0.10%
F.L. Putnam Investment Management Co. 189,710 0.069%
Boston Private Wealth LLC 189,710 0.069%
J. M. Forbes & Co. LLP 73,500 0.027%
Company contact information
ProMIS Neurosciences, Inc.
1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2

Phone : +1.416.847.6898
Fax : +1.416.847.6899
Web : http://www.promisneurosciences.com
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
PROMIS NEUROSCIENCES, INC.29.41%47
GILEAD SCIENCES, INC.17.50%95 771
VERTEX PHARMACEUTICALS32.95%75 475
REGENERON PHARMACEUTICALS65.77%63 212
WUXI APPTEC CO., LTD.45.70%31 226
GENMAB A/S49.85%21 887
BEIGENE, LTD.18.16%15 294
BIONTECH SE86.75%14 348
SAREPTA THERAPEUTICS, INC.26.12%12 693
HUALAN BIOLOGICAL ENGINEERING INC.75.23%12 232
NEUROCRINE BIOSCIENCES, INC.16.63%11 643
ARGENX SE46.52%11 119
EXELIXIS, INC.33.26%7 200
ASCENDIS PHARMA A/S8.54%6 676
BIOCON LIMITED34.70%6 282
ZAI LAB LIMITED95.00%6 056
ACCELERON PHARMA INC.91.15%5 948
PEPTIDREAM INC.-13.84%5 644
REATA PHARMACEUTICALS, INC.-22.79%5 247
ULTRAGENYX PHARMACEUTICAL INC.101.45%5 141
MIRATI THERAPEUTICS, INC.-9.21%5 106